Colorado Democratic Rep. Diana DeGette, who lost her primary, was knowledgeable about biopharma, if not always a friend to the industry. Obesity research FDA Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter D.C. Diagnosis What does DeGette’s loss mean for pharma? You’re reading STAT’s D.C. Diagnosis…
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
RFK Jr. said on Fox News that he’ll leave raccoons alone “for the moment.” Send news tips and ideas for roadkill excursions to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.
DeGette’s loss is a mixed bag for drug industry
The drug industry will lose a key Democratic lawmaker who was knowledgeable about the industry, if not always a friend.
Continue to STAT+ to read the full story…
US Pharma Marketing